title: SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
authors.affiliation: Department of Gastroenterology and Hepatology, AZ Groeninge Hospital, Kortrijk, Belgium.
authors.forename: François
authors.initials: F
authors.lastname: D'heygere
authors.affiliation: Department of Gastroenterology and Hepatology, AZ Groeninge Hospital, Kortrijk, Belgium.
authors.forename: Christophe
authors.initials: C
authors.lastname: George
authors.affiliation: Pôle Hépato-digestif, Unité Inserm U.1110, Université de Strasbourg, Laboratoire d'Excellence HepSys, Strasbourg, France.
authors.forename: François
authors.initials: F
authors.lastname: Habersetzer
authors.affiliation: Southlake Regional Health Centre, Newmarket, ON, Canada.
authors.forename: Davender
authors.initials: D
authors.lastname: Tripathi
authors.affiliation: Division of Gastroenterology, .Department of Medicine, NYU Langone Medical Center, New York University School of Medicine, New York, NY, USA.
authors.forename: Calvin
authors.initials: C
authors.lastname: Q Pan
authors.affiliation: Orlando Infectious Disease Center, Orlando, FL, USA.
authors.forename: Jose A
authors.initials: JA
authors.lastname: Giron
authors.affiliation: IST GmbH, Mannheim, Germany.
authors.forename: Manuela
authors.initials: M
authors.lastname: Schmitz
authors.affiliation: F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors.forename: Fernando
authors.initials: F
authors.lastname: Tatsch
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D064792:Pragmatic Clinical Trials as Topic; D012367:RNA, Viral / Q000097:blood*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a